Provision of Amplidiag Easy instruments
A Contract Award Notice
by PUBLIC HEALTH ENGLAND
- Source
- Find a Tender
- Type
- Contract (Supply)
- Duration
- not specified
- Value
- £300K
- Sector
- HEALTH
- Published
- 29 Jan 2021
- Delivery
- not specified
- Deadline
- n/a
Concepts
Location
Salisbury
2 buyers
- Public Health England Salisbury
1 supplier
- Mobidiag High Wycombe
Description
Public Health England(PHE) has awarded a contract to Mobidiag UK Ltd for the provision of high volume Amplidiag with integrated CFX systems. PHE discharges its duties as a Category 1 Responder to emergencies on behalf of the Secretary of State for Health within the scope of the Civil Contingencies Act 2004 (CCA 2004).
Total Quantity or Scope
This single tender action request is for the purpose of procuring high volume Amplidiag with integrated CFX systems. This solution will Increase molecular extraction and amplification capacity to provide immediate increase throughput of the COVID-19 assay and subsequent respiratory syndromic end to end solution for patients.
Award Detail
1 | Mobidiag (High Wycombe)
|
Award Criteria
PRICE | _ |
CPV Codes
- 33124110 - Diagnostic systems
- 38951000 - Real-time Polymerase Chain Reaction (PCR) equipment
Indicators
- Award on basis of price.
Legal Justification
The Government must protect the health and well-being of UK citizens. The COVID-19 outbreak is a Public Health Emergency of International Concern (PHEIC) as declared by the World Health Organisation on 30 Jan 2020. The WHO Director General characterised COVID-19 as a pandemic on 11 Mar 2020. PHE discharges its duties as a Category 1 Responder to emergencies on behalf of the Secretary of State for Health within the scope of the Civil Contingencies Act 2004 (CCA 2004). This urgent requirement is in response to the COVID -19 outbreak. A direct award has been made due to extreme urgency under current public procurement regulations using regulation 32(2)(c) for the purpose of procuring high volume Amplidiag with integrated CFX systems. This solution will be used to increase the throughput of the COVID-19 assays and subsequent respiratory syndromic end to end solution for patients.
Reference
- FTS 001902-2021